Serial	O
measurements	O
of	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
in	O
patients	O
with	O
systemic	O
vasculitis	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
value	O
of	O
serial	O
determinations	O
of	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
(	O
ANCA	O
)	O
for	O
monitoring	O
disease	O
activity	O
in	O
patients	O
with	O
systemic	O
vasculitis	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
three	O
patients	O
with	O
histologically	O
proven	O
vasculitis	O
(	O
21	O
with	O
Wegener	O
's	O
granulomatosis	O
,	O
17	O
with	O
microscopic	O
polyangiitis	O
,	O
and	O
5	O
with	O
renal	O
-	O
limited	O
vasculitis	O
)	O
were	O
studied	O
for	O
a	O
median	O
follow	O
-	O
up	O
of	O
22	O
months	O
.	O

Disease	O
activity	O
was	O
prospectively	O
assessed	O
and	O
quantified	O
by	O
the	O
Birmingham	O
Vasculitis	O
Activity	O
Score	O
.	O

A	O
total	O
of	O
347	O
sera	O
were	O
analyzed	O
for	O
ANCA	O
determination	O
.	O

RESULTS	O
:	O
Relapses	O
occurred	O
in	O
23	O
(	O
54	O
%	O
)	O
of	O
43	O
patients	O
.	O

Diagnostic	O
category	O
(	O
Wegener	O
's	O
granulomatosis	O
vs	O
micropolyangiitis	O
and	O
renal	O
-	O
limited	O
vasculitis	O
)	O
,	O
severity	O
of	O
initial	O
symptoms	O
(	O
mean	O
vasculitis	O
activity	O
score	O
,	O
mean	O
number	O
of	O
organs	O
involved	O
)	O
,	O
and	O
ANCA	O
pattern	O
[	O
cytoplasmic	O
-	O
ANCA	O
(	O
c	O
-	O
ANCA	O
)	O
vs	O
perinuclear	O
-	O
ANCA	O
(	O
p	O
-	O
ANCA	O
)	O
]	O
did	O
not	O
significantly	O
differ	O
between	O
relapsers	O
and	O
nonrelapsers	O
.	O

Lung	O
involvement	O
was	O
more	O
frequent	O
at	O
onset	O
among	O
relapsers	O
[	O
16	O
of	O
23	O
(	O
)	O
vs	O
6	O
of	O
(	O
)	O
;	O
P	O
=	O
0.02	O
]	O
.	O

Relapses	O
were	O
slightly	O
,	O
but	O
not	O
significantly	O
,	O
more	O
frequent	O
in	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
or	O
a	O
c	O
-	O
ANCA	O
pattern	O
.	O

The	O
percentage	O
of	O
relapsers	O
was	O
greater	O
in	O
patients	O
with	O
persistently	O
positive	O
ANCA	O
than	O
in	O
patients	O
with	O
negative	O
or	O
decreasing	O
ANCA	O
titers	O
(	O
86	O
%	O
vs	O
,	O
P	O
=	O
0.0001	O
)	O
.	O

However	O
,	O
the	O
predictive	O
value	O
of	O
an	O
increase	O
in	O
ANCA	O
titers	O
for	O
the	O
occurrence	O
of	O
a	O
subsequent	O
relapse	O
was	O
only	O
28	O
%	O
(	O
4	O
of	O
14	O
)	O
for	O
c	O
-	O
ANCA	O
,	O
12	O
%	O
(	O
2	O
of	O
17	O
)	O
for	O
anti	O
-	O
proteinase	O
3	O
-	O
ANCA	O
,	O
and	O
43	O
%	O
(	O
6	O
of	O
14	O
)	O
for	O
anti	O
-	O
myeloperoxidase	O
-	O
ANCA	O
.	O

An	O
increase	O
in	O
ANCA	O
occurred	O
before	O
or	O
during	O
relapse	O
in	O
33	O
%	O
(	O
of	O
)	O
of	O
cases	O
for	O
c	O
-	O
ANCA	O
/	O
anti	O
-	O
proteinase	O
3	O
antibodies	O
,	O
and	O
73	O
%	O
(	O
11	O
of	O
15	O
)	O
of	O
cases	O
for	O
anti	O
-	O
myeloperoxidase	O
antibodies	O
.	O

CONCLUSION	O
:	O
The	O
persistence	O
of	O
ANCA	O
positivity	O
is	O
strongly	O
associated	O
with	O
relapses	O
.	O

However	O
,	O
an	O
increase	O
in	O
ANCA	O
titers	O
has	O
a	O
poor	O
value	O
for	O
the	O
early	O
prediction	O
of	O
a	O
subsequent	O
relapse	O
and	O
should	O
not	O
be	O
used	O
as	O
a	O
sole	O
parameter	O
for	O
therapeutic	O
intervention	O
.	O

In	O
addition	O
,	O
our	O
results	O
suggest	O
that	O
serial	O
anti	O
-	O
myeloperoxidase	O
determination	O
may	O
be	O
useful	O
as	O
a	O
prognostic	O
marker	O
in	O
patients	O
who	O
are	O
p	O
-	O
ANCA	O
positive	O
.	O

Serum	O
lipid	B
and	O
leptin	O
concentrations	O
in	O
hypopituitary	O
patients	O
with	O
growth	O
hormone	O
deficiency	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
deficiency	O
on	O
serum	O
lipid	B
and	O
leptin	O
concentrations	O
in	O
hypopituitary	O
patients	O
taking	O
conventional	O
replacement	O
therapy	O
and	O
to	O
determine	O
the	O
relations	O
between	O
leptin	O
and	O
gender	O
and	O
anthropometric	O
and	O
metabolic	O
variables	O
.	O

SUBJECTS	O
:	O
Twenty	O
-	O
one	O
GH	O
deficient	O
adult	O
hypopituitary	O
patients	O
(	O
15	O
women	O
,	O
six	O
men	O
)	O
and	O
21	O
(	O
14	O
women	O
,	O
seven	O
men	O
)	O
age	O
,	O
sex	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
matched	O
healthy	O
controls	O
.	O

MEASUREMENTS	O
:	O
After	O
an	O
overnight	O
fast	O
,	O
anthropometric	O
parameters	O
were	O
measured	O
and	O
body	O
composition	O
was	O
determined	O
by	O
a	O
bioelectrical	O
impedance	O
analyser	O
.	O

Venous	O
blood	O
samples	O
were	O
obtained	O
for	O
the	O
measurements	O
of	O
glucose	B
,	O
total	O
cholesterol	B
,	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B
,	O
triglyceride	B
,	O
intact	O
insulin	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
(	O
IGF	O
-	O
1	O
)	O
and	O
leptin	O
concentrations	O
.	O

Serum	O
leptin	O
and	O
hormones	O
were	O
analysed	O
by	O
radioimmunoassay	O
.	O

RESULTS	O
:	O
Hypopituitary	O
patients	O
with	O
GH	O
deficiency	O
showed	O
significantly	O
higher	O
triglyceride	B
,	O
total	O
and	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	B
and	O
lower	O
HDL	O
cholesterol	B
concentrations	O
on	O
conventional	O
replacement	O
therapy	O
.	O

The	O
unfavourable	O
lipid	B
profile	O
was	O
particularly	O
evident	O
in	O
women	O
.	O

Significantly	O
higher	O
leptin	O
concentrations	O
were	O
found	O
in	O
patients	O
compared	O
with	O
healthy	O
controls	O
with	O
similar	O
body	O
fat	O
content	O
(	O
23	O
.	O
5	O
+	O
/	O
-	O
11.8	O
ng	O
/	O
ml	O
vs	O
11.7	O
+	O
/	O
-	O
6.9	O
ng	O
/	O
ml	O
,	O
P	O
=	O
0.01	O
)	O
.	O

This	O
difference	O
remained	O
significant	O
even	O
when	O
leptin	O
values	O
were	O
expressed	O
in	O
relation	O
to	O
fat	O
mass	O
percentage	O
(	O
0.79	O
+	O
/	O
-	O
0.40	O
vs.	O
0.42	O
+	O
/	O
-	O
0.17	O
ng	O
/	O
ml	O
%	O
,	O
P	O
<	O
0.05	O
)	O
and	O
fat	O
mass	O
kg	O
(	O
1.32	O
+	O
/	O
-	O
0.81	O
vs	O
0.66	O
+	O
/	O
-	O
0.30	O
ng	O
/	O
ml	O
kg	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Significant	O
positive	O
correlations	O
were	O
observed	O
between	O
leptin	O
concentrations	O
and	O
body	O
fat	O
percentage	O
and	O
age	O
in	O
the	O
control	O
group	O
.	O

In	O
patients	O
the	O
sole	O
significant	O
relation	O
between	O
leptin	O
and	O
study	O
parameters	O
was	O
the	O
positive	O
correlation	O
observed	O
between	O
leptin	O
and	O
total	O
cholesterol	B
concentrations	O
.	O

Serum	O
leptin	O
concentrations	O
were	O
significantly	O
higher	O
in	O
women	O
than	O
men	O
in	O
the	O
control	O
group	O
,	O
but	O
not	O
in	O
the	O
patients	O
.	O

No	O
significant	O
gender	O
difference	O
was	O
observed	O
when	O
leptin	O
concentrations	O
were	O
expressed	O
in	O
relation	O
to	O
fat	O
mass	O
(	O
percentage	O
and	O
kg	O
)	O
.	O

CONCLUSION	O
:	O
Growth	O
hormone	O
deficient	O
hypopituitary	O
patients	O
(	O
particularly	O
women	O
)	O
on	O
conventional	O
replacement	O
therapy	O
have	O
a	O
more	O
atherogenic	O
lipid	B
profile	O
.	O

Leptin	O
concentrations	O
are	O
increased	O
in	O
GH	O
deficient	O
adults	O
even	O
after	O
adjustment	O
for	O
percentage	O
body	O
fat	O
and	O
body	O
fat	O
mass	O
(	O
kg	O
)	O
.	O

Although	O
the	O
nature	O
of	O
our	O
data	O
does	O
not	O
allow	O
us	O
to	O
draw	O
any	O
conclusions	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
increased	O
leptin	O
concentrations	O
in	O
GH	O
deficiency	O
,	O
decreased	O
central	O
sensitivity	O
to	O
leptin	O
and	O
increased	O
leptin	O
production	O
from	O
per	O
unit	O
fat	O
mass	O
,	O
or	O
alterations	O
in	O
leptin	O
clearance	O
,	O
might	O
be	O
operative	O
.	O

At	O
physiological	O
pH	O
,	O
the	O
spatial	O
arrangement	O
of	O
the	O
three	O
charges	O
of	O
DL	B
-	I
tetrazol	I
-	I
5	I
-	I
ylglycine	I
(	O
5	O
)	O
could	O
be	O
viewed	O
as	O
similar	O
to	O
those	O
found	O
in	O
certain	O
conformations	O
of	O
the	O
two	O
excitatory	O
amino	O
acids	O
(	O
EAAs	O
)	O
-	O
-	O
aspartic	B
and	O
glutamic	B
acids	I
.	O

Given	O
significant	O
binding	O
to	O
one	O
or	O
more	O
EAA	O
receptors	O
,	O
5	O
would	O
offer	O
unique	O
modeling	O
and	O
perhaps	O
biological	O
opportunities	O
.	O

We	O
have	O
previously	O
shown	O
it	O
to	O
be	O
the	O
most	O
potent	O
NMDA	B
agonist	O
known	O
,	O
with	O
a	O
unique	O
and	O
marked	O
in	O
vitro	O
neutrotoxicity	O
at	O
depolarizing	O
concentrations	O
.	O

Now	O
we	O
report	O
the	O
details	O
required	O
for	O
its	O
synthesis	O
,	O
together	O
with	O
its	O
potency	O
and	O
efficacy	O
in	O
two	O
assays	O
of	O
functional	O
activation	O
of	O
the	O
NMDA	O
receptor	O
,	O
namely	O
agonist	O
-	O
influenced	O
[	B
3H	I
]	I
MK801	I
binding	O
and	O
agonist	O
-	O
induced	O
release	O
of	O
the	O
neurotransmitter	O
[	B
3H	I
]	I
-	I
norepinephrine	I
from	O
brain	O
slices	O
.	O

In	O
both	O
these	O
assays	O
DL	B
-	I
tetrazol	I
-	I
5	I
-	I
ylglycine	I
proved	O
to	O
be	O
more	O
potent	O
and	O
efficacious	O
than	O
NMDA	B
and	O
cis	B
-	I
methanoglutamate	I
.	O

It	O
was	O
more	O
potent	O
than	O
,	O
and	O
equally	O
efficacious	O
to	O
,	O
L	B
-	I
glutamate	I
in	O
[	B
3H	I
]	I
MK801	I
binding	O
.	O

The	O
structural	O
features	O
of	O
5	O
may	O
well	O
reflect	O
optimal	O
agonist	O
interaction	O
at	O
the	O
NMDA	O
receptor	O
site	O
.	O

(	O
We	O
considered	O
the	O
possibility	O
that	O
some	O
decarboxylation	O
of	O
DL	B
-	I
tetrazol	I
-	I
5	I
-	I
ylglycine	I
may	O
have	O
occurred	O
during	O
testing	O
.	O

This	O
would	O
give	O
5	B
-	I
(	I
aminomethyl	I
)	I
tetrazole	I
(	O
13	O
)	O
,	O
the	O
tetrazole	B
acid	I
analog	B
of	O
glycine	B
;	O
and	O
glycine	B
is	O
involved	O
in	O
NMDA	O
receptor	O
activation	O
.	O

Compound	O
13	O
does	O
not	O
affect	O
[	B
3H	I
]	I
glycine	I
binding	O
at	O
the	O
strychnine	B
-	O
insensitive	O
glycine	B
binding	O
site	O
,	O
and	O
[	B
3H	I
]	I
MK801	I
binding	O
studies	O
showed	O
that	O
the	O
(	B
aminomethyl	I
)	I
-	I
tetrazole	I
,	O
even	O
if	O
is	O
formed	O
,	O
would	O
probably	O
have	O
no	O
effect	O
on	O
the	O
activity	O
of	O
tetrazol	B
-	I
5	I
-	I
ylglycine	I
at	O
the	O
NMDA	O
receptor	O
.	O

Implied	O
preference	O
for	O
seismic	O
design	O
level	O
and	O
earthquake	O
insurance	O
.	O

Seismic	O
risk	O
can	O
be	O
reduced	O
by	O
implementing	O
newly	O
developed	O
seismic	O
provisions	O
in	O
design	O
codes	O
.	O

Furthermore	O
,	O
financial	O
protection	O
or	O
enhanced	O
utility	O
and	O
happiness	O
for	O
stakeholders	O
could	O
be	O
gained	O
through	O
the	O
purchase	O
of	O
earthquake	O
insurance	O
.	O

If	O
this	O
is	O
not	O
so	O
,	O
there	O
would	O
be	O
no	O
market	O
for	O
such	O
insurance	O
.	O

However	O
,	O
perceived	O
benefit	O
associated	O
with	O
insurance	O
is	O
not	O
universally	O
shared	O
by	O
stakeholders	O
partly	O
due	O
to	O
their	O
diverse	O
risk	O
attitudes	O
.	O

This	O
study	O
investigates	O
the	O
implied	O
seismic	O
design	O
preference	O
with	O
insurance	O
options	O
for	O
decisionmakers	O
of	O
bounded	O
rationality	O
whose	O
preferences	O
could	O
be	O
adequately	O
represented	O
by	O
the	O
cumulative	O
prospect	O
theory	O
(	O
CPT	O
)	O
.	O

The	O
investigation	O
is	O
focused	O
on	O
assessing	O
the	O
sensitivity	O
of	O
the	O
implied	O
seismic	O
design	O
preference	O
with	O
insurance	O
options	O
to	O
model	O
parameters	O
of	O
the	O
CPT	O
and	O
to	O
fair	O
and	O
unfair	O
insurance	O
arrangements	O
.	O

Numerical	O
results	O
suggest	O
that	O
human	O
cognitive	O
limitation	O
and	O
risk	O
perception	O
can	O
affect	O
the	O
implied	O
seismic	O
design	O
preference	O
by	O
the	O
CPT	O
significantly	O
.	O

The	O
mandatory	O
purchase	O
of	O
fair	O
insurance	O
will	O
lead	O
the	O
implied	O
seismic	O
design	O
preference	O
to	O
the	O
optimum	O
design	O
level	O
that	O
is	O
dictated	O
by	O
the	O
minimum	O
expected	O
lifecycle	O
cost	O
rule	O
.	O

Unfair	O
insurance	O
decreases	O
the	O
expected	O
gain	O
as	O
well	O
as	O
its	O
associated	O
variability	O
,	O
which	O
is	O
preferred	O
by	O
risk	O
-	O
averse	O
decisionmakers	O
.	O

The	O
obtained	O
results	O
of	O
the	O
implied	O
preference	O
for	O
the	O
combination	O
of	O
the	O
seismic	O
design	O
level	O
and	O
insurance	O
option	O
suggest	O
that	O
property	O
owners	O
,	O
financial	O
institutions	O
,	O
and	O
municipalities	O
can	O
take	O
advantage	O
of	O
affordable	O
insurance	O
to	O
establish	O
successful	O
seismic	O
risk	O
management	O
strategies	O
.	O

Oribatid	O
Mite	O
Communities	O
in	O
the	O
Canopy	O
of	O
Montane	O
Abies	O
amabilis	O
and	O
Tsuga	O
heterophylla	O
Trees	O
on	O
Vancouver	O
Island	O
,	O
British	O
Columbia	O
.	O

To	O
study	O
the	O
oribatid	O
mite	O
community	O
inhabiting	O
microhabitats	O
in	O
the	O
canopy	O
of	O
montane	O
Abies	O
amabilis	O
[	O
(	O
Douglas	O
ex	O
D	O
.	O

Don	O
)	O
Lindl	O
.	O
]	O
and	O
Tsuga	O
heterophylla	O
[	O
(	O
Raf	O
.	O
)	O

Sarg	O
]	O
tree	O
species	O
across	O
five	O
elevational	O
sites	O
,	O
we	O
collected	O
branch	O
tips	O
and	O
foliose	O
/	O
crustose	O
lichen	O
samples	O
over	O
three	O
time	O
periods	O
.	O

Thirty	O
-	O
three	O
species	O
of	O
oribatid	O
mites	O
were	O
identified	O
from	O
the	O
study	O
area	O
.	O

Mite	O
species	O
richness	O
and	O
abundance	O
was	O
significantly	O
affected	O
by	O
microhabitat	O
,	O
and	O
this	O
association	O
was	O
independent	O
of	O
sampling	O
time	O
.	O

At	O
the	O
microhabitat	O
scale	O
,	O
distinct	O
species	O
assemblages	O
were	O
associated	O
with	O
lichen	O
and	O
branch	O
tip	O
habitats	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
,	O
tree	O
species	O
.	O

Conifer	O
specificity	O
was	O
most	O
apparent	O
in	O
the	O
closely	O
related	O
species	O
of	O
Jugatala	O
,	O
where	O
Jugatala	O
tuberosa	O
Ewing	O
was	O
only	O
found	O
on	O
branch	O
tips	O
from	O
A	O
.	O

amabilis	O
and	O
Jugatala	O
sp	O
.	O
was	O
primarily	O
found	O
on	O
branch	O
tips	O
from	O
T	O
.	O

heterophylla	O
.	O

Microhabitat	O
specificity	O
was	O
most	O
pronounced	O
in	O
Dendrozetes	O
sp	O
.	O

where	O
most	O
individuals	O
were	O
found	O
on	O
branch	O
tips	O
and	O
Anachiperia	O
geminus	O
Lindo	O
et	O
al.	O
that	O
occurred	O
primarily	O
on	O
lichens	O
.	O

Principal	O
components	O
analysis	O
of	O
oribatid	O
mite	O
community	O
composition	O
further	O
showed	O
a	O
high	O
degree	O
of	O
association	O
with	O
microhabitat	O
and	O
tree	O
species	O
.	O

Habitat	O
profiles	O
are	O
difficult	O
to	O
discern	O
for	O
many	O
species	O
because	O
tree	O
,	O
microhabitat	O
,	O
and	O
elevation	O
preferences	O
confound	O
distribution	O
patterns	O
.	O

Given	O
the	O
significant	O
tree	O
-	O
microhabitat	O
associations	O
in	O
species	O
composition	O
in	O
this	O
montane	O
canopy	O
study	O
,	O
we	O
suggest	O
that	O
sampling	O
multiple	O
microhabitats	O
across	O
elevations	O
to	O
look	O
for	O
patterns	O
in	O
community	O
structure	O
offers	O
opportunities	O
to	O
explicitly	O
test	O
organizing	O
principles	O
in	O
community	O
ecology	O
.	O

Unilateral	O
hearing	O
disturbance	O
could	O
be	O
an	O
isolated	O
manifestation	O
prior	O
to	O
ipsilateral	O
anterior	O
inferior	O
cerebellar	O
artery	O
infarction	O
.	O

A	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
a	O
sudden	O
onset	O
of	O
right	O
-	O
sided	O
hearing	O
disturbance	O
.	O

His	O
hearing	O
disturbance	O
improved	O
gradually	O
,	O
however	O
,	O
dysarthria	O
,	O
right	O
-	O
sided	O
facial	O
weakness	O
and	O
dysesthesia	O
,	O
and	O
gait	O
disturbance	O
was	O
developed	O
11	O
days	O
after	O
the	O
onset	O
of	O
hearing	O
disturbance	O
.	O

MR	O
imaging	O
revealed	O
fresh	O
infarctions	O
of	O
the	O
right	O
dorsolateral	O
pons	O
and	O
middle	O
cerebellar	O
peduncle	O
localized	O
in	O
the	O
territory	O
of	O
anterior	O
inferior	O
cerebellar	O
artery	O
.	O

Unilateral	O
hearing	O
disturbance	O
could	O
be	O
an	O
isolated	O
manifestation	O
prior	O
to	O
ipsilateral	O
anterior	O
inferior	O
cerebellar	O
artery	O
infarction	O
.	O

The	O
synthesis	O
of	O
2	B
'	I
-	I
fluoro	I
-	I
-	I
propargyl	I
-	I
5,8	I
-	I
dideazafolic	I
acid	I
and	O
its	O
2	B
-	I
desamino	I
,	O
2	B
-	I
desamino	I
-	I
2	I
-	I
hydroxymethyl	I
,	O
and	O
2	B
-	I
desamino	I
-	I
2	I
-	I
methoxy	I
analogues	B
is	O
described	O
.	O

In	O
general	O
the	O
synthetic	O
route	O
involved	O
the	O
coupling	O
of	O
diethyl	B
N	I
-	I
[	I
2	I
-	I
fluoro	I
-	I
4	I
-	I
(	I
prop	I
-	I
2	I
-	I
ynylamino	I
)	I
benzoyl	I
]	I
-	I
L	I
-	I
glutamate	I
with	O
the	O
appropriate	O
6	B
-	I
(	I
bromomethyl	I
)	I
quinazoline	I
followed	O
by	O
deprotection	O
with	O
mild	O
alkali	O
.	O

These	O
four	O
compounds	O
together	O
with	O
the	O
2	B
-	I
desamino	I
-	I
2	I
-	I
methyl	I
analogue	B
were	O
tested	O
for	O
their	O
activity	O
against	O
L1210	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
.	O

They	O
were	O
also	O
examined	O
for	O
their	O
inhibition	O
of	O
the	O
growth	O
of	O
the	O
L1210	O
cell	O
line	O
and	O
of	O
two	O
mutant	O
L1210	O
cell	O
lines	O
,	O
the	O
L1210	O
:	O
R7A	O
that	O
overproduces	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
and	O
the	O
L1210	O
:	O
1565	O
that	O
has	O
impaired	O
uptake	O
of	O
reduced	O
folates	O
.	O

Compared	O
with	O
their	O
non	O
-	O
fluorinated	O
parent	O
compounds	O
,	O
the	O
2	B
'	I
-	I
fluoro	I
analogues	B
were	O
all	O
approximately	O
2	O
-	O
fold	O
more	O
potent	O
as	O
TS	O
inhibitors	O
.	O

Similarly	O
,	O
they	O
also	O
showed	O
improved	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
(	O
1.5	O
-	O
5	O
-	O
fold	O
)	O
,	O
and	O
this	O
activity	O
was	O
prevented	O
by	O
co	O
-	O
incubation	O
with	O
thymidine	O
.	O

All	O
had	O
retained	O
or	O
improved	O
activity	O
against	O
both	O
the	O
L1210	O
:	O
R7A	O
and	O
L1210	O
:	O
1565	O
cell	O
lines	O
.	O

N	O
-	O
Methylacetazolamide	O
was	O
shown	O
to	O
be	O
active	O
topically	O
in	O
reducing	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
to	O
a	O
small	O
but	O
statistically	O
significant	O
level	O
in	O
the	O
normotensive	O
rabbit	O
eye	O
.	O

In	O
vivo	O
experiments	O
with	O
N	B
-	I
methylacetazolamide	I
suggest	O
that	O
ocular	O
metabolism	O
to	O
acetazolamide	B
was	O
responsible	O
for	O
the	O
observed	O
topical	O
activity	O
.	O

Examination	O
of	O
initial	O
rate	O
kinetics	O
of	O
carbonic	O
anhydrase	O
catalyzed	O
p	B
-	I
nitrophenyl	I
acetate	I
hydrolysis	O
showed	O
that	O
N	B
-	I
methylacetazolamide	I
was	O
a	O
competitive	O
inhibitor	O
,	O
in	O
contrast	O
to	O
noncompetitive	O
inhibition	O
seen	O
with	O
acetazolamide	B
and	O
other	O
primary	O
sulfonamide	B
inhibitors	O
.	O

N	B
-	I
Substituted	I
and	O
unsubstituted	B
4	I
-	I
chlorobenzene	I
-	I
and	O
4	B
-	I
nitrobenzenesulfonamides	I
were	O
also	O
synthesized	O
,	O
and	O
their	O
biochemical	O
characteristics	O
and	O
in	O
vivo	O
ability	O
to	O
lower	O
IOP	O
when	O
applied	O
topically	O
were	O
determined	O
.	O

The	O
primary	O
sulfonamides	B
were	O
reversible	O
noncompetitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
with	O
no	O
effect	O
on	O
IOP	O
after	O
topical	O
administration	O
.	O

4	B
-	I
Nitrobenzene	I
-	I
and	O
4	B
-	I
chlorobenzenesulfonamides	I
containing	O
both	O
N	B
-	I
hydroxy	I
and	O
N	B
-	I
methyl	I
substituents	B
were	O
model	O
irreversible	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
and	O
exhibited	O
a	O
trend	O
toward	O
topical	O
activity	O
in	O
reducing	O
IOP	O
in	O
normotensive	O
rabbit	O
eyes	O
.	O

Therefore	O
,	O
this	O
paper	O
describes	O
the	O
synthesis	O
and	O
characterization	O
of	O
two	O
types	O
of	O
carbonic	O
anhydrase	O
inhibitors	O
;	O
the	O
N	B
-	I
methyl	I
-	I
substituted	I
sulfonamides	I
are	O
reversible	O
competitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
while	O
the	O
N	B
-	I
hydroxy	I
-	I
N	I
-	I
methyl	I
-	I
substituted	I
sulfonamides	I
are	O
irreversible	O
inhibitors	O
.	O

This	O
study	O
emphasizes	O
the	O
importance	O
of	O
the	O
metabolic	O
conversion	O
of	O
the	O
enantiomers	O
of	O
3	B
-	I
(	I
3	I
-	I
hydroxyphenyl	I
)	I
-	I
N	I
-	I
n	I
-	I
propylpiperidine	I
(	O
3	B
-	I
PPP	I
)	O
into	O
their	O
catechol	B
analogues	B
,	O
the	O
enantiomers	O
of	O
3	B
-	I
(	I
3,4	I
-	I
dihydroxyphenyl	I
)	I
-	I
N	I
-	I
n	I
-	I
propylpiperidine	I
.	O

These	O
isomers	O
are	O
both	O
shown	O
to	O
be	O
excellent	O
substrates	O
for	O
COMT	O
,	O
with	O
a	O
slight	O
preference	O
for	O
the	O
S	O
-	O
(	O
-	O
)	O
enantiomer	O
.	O

Assessment	O
of	O
the	O
dopaminergic	O
activity	O
of	O
these	O
catechols	O
and	O
the	O
results	O
from	O
the	O
determination	O
of	O
brain	O
levels	O
of	O
the	O
enantiomers	O
of	O
3	B
-	I
PPP	I
and	O
their	O
metabolites	O
indicate	O
that	O
the	O
metabolites	O
probably	O
do	O
not	O
alter	O
the	O
pharmacological	O
profiles	O
established	O
for	O
(	B
R	I
)	I
-	I
(	I
+	I
)	I
-	I
and	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
.	O

The	O
conversion	O
of	O
the	O
monophenols	B
into	O
catecholic	O
metabolites	O
is	O
only	O
1	O
-	O
5	O
%	O
,	O
and	O
the	O
further	O
conversion	O
of	O
these	O
catecholic	O
metabolites	O
into	O
methoxylated	O
analogues	O
is	O
very	O
rapid	O
.	O

However	O
,	O
the	O
very	O
interesting	O
observation	O
was	O
made	O
that	O
,	O
when	O
inhibiting	O
COMT	O
by	O
means	O
of	O
tropolone	B
and	O
subsequently	O
treating	O
the	O
rats	O
with	O
high	O
doses	O
of	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
(	O
ip	O
)	O
,	O
postsynaptic	O
dopaminergic	O
activity	O
was	O
elicited	O
.	O

This	O
has	O
never	O
been	O
seen	O
for	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
without	O
tropolone	B
pretreatment	O
and	O
might	O
indicate	O
that	O
,	O
in	O
this	O
special	O
case	O
,	O
the	O
catecholic	O
metabolite	O
affects	O
the	O
in	O
vivo	O
pharmacological	O
profile	O
of	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
.	O

The	O
syntheses	O
and	O
anthelmintic	O
activities	O
of	O
31	O
3	B
-	I
and	O
5	B
-	I
(	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazoles	I
are	O
reported	O
.	O

In	O
the	O
primary	O
anthelmintic	O
screen	O
,	O
3	B
-	I
(	I
4	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
39	O
)	O
showed	O
nematocidal	O
activity	O
and	O
3	B
-	I
(	I
2	I
-	I
furanyl	I
)	I
-	I
5	I
-	I
(	I
4	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
63	O
)	O
,	O
3	B
-	I
(	I
2	I
-	I
furanyl	I
)	I
-	I
5	I
-	I
(	I
2	I
-	I
chloro	I
-	I
4	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
64	O
)	O
,	O
and	O
3	B
-	I
(	I
2	I
-	I
furanyl	I
)	I
-	I
5	I
-	I
(	I
4	I
-	I
chloro	I
-	I
3	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
66	O
)	O
showed	O
taeniacidal	O
activity	O
when	O
administered	O
orally	O
to	O
mice	O
.	O

The	O
two	O
most	O
active	O
members	O
of	O
this	O
series	O
,	O
39	O
and	O
63	O
,	O
were	O
active	O
against	O
the	O
gastrointestinal	O
nematodes	O
of	O
sheep	O
at	O
mg	O
/	O
kg	O
.	O

In	O
addition	O
,	O
39	O
was	O
also	O
found	O
to	O
be	O
active	O
against	O
hookworms	O
in	O
dogs	O
at	O
a	O
single	O
,	O
oral	O
dose	O
of	O
mg	O
/	O
kg	O
.	O

